These pathways may explain the LAZ3-mediated anti-inflammatory and anti-oxidative activities in the DCM heart, as both Nrf2 knockdown and PPARα agonists can reverse the effects of LAZ3 overexpression or silencing (Gao et al., 2018). This evidence concerns the gene PPARA and familial dilated cardiomyopathy.